• Something wrong with this record ?

RGD delivery of truncated coagulase to tumor vasculature affords local thrombotic activity to induce infarction of tumors in mice

R. Jahanban-Esfahlan, K. Seidi, H. Monhemi, ADF. Adli, B. Minofar, P. Zare, D. Farajzadeh, S. Farajnia, R. Behzadi, MM. Abbasi, N. Zarghami, T. Javaheri,

. 2017 ; 7 (1) : 8126. [pub] 20170815

Language English Country England, Great Britain

Document type Journal Article, Research Support, Non-U.S. Gov't

Persistent link   https://www.medvik.cz/link/bmc19013093

Induction of thrombosis in tumor vasculature represents an appealing strategy for combating cancer. Herein, we combined unique intrinsic coagulation properties of staphylocoagulase with new acquired functional potentials introduced by genetic engineering, to generate a novel bi-functional fusion protein consisting of truncated coagulase (tCoa) bearing an RGD motif on its C-terminus for cancer therapy. We demonstrated that free coagulase failed to elicit any significant thrombotic activity. Conversely, RGD delivery of coagulase retained coagulase activity and afforded favorable interaction of fusion proteins with prothrombin and αvβ3 endothelial cell receptors, as verified by in silico, in vitro, and in vivo experiments. Although free coagulase elicited robust coagulase activity in vitro, only targeted coagulase (tCoa-RGD) was capable of producing extensive thrombosis, and subsequent infarction and massive necrosis of CT26 mouse colon, 4T1 mouse mammary and SKOV3 human ovarian tumors in mice. Additionally, systemic injections of lower doses of tCoa-RGD produced striking tumor growth inhibition of CT26, 4T1 and SKOV3 solid tumors in animals. Altogether, the nontoxic nature, unique shortcut mechanism, minimal effective dose, wide therapeutic window, efficient induction of thrombosis, local effects and susceptibility of human blood to coagulase suggest tCoa-RGD fusion proteins as a novel and promising anticancer therapy for human trials.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc19013093
003      
CZ-PrNML
005      
20190405092903.0
007      
ta
008      
190405s2017 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1038/s41598-017-05326-9 $2 doi
035    __
$a (PubMed)28811469
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Jahanban-Esfahlan, Rana $u Department of Medical Biotechnology, Faculty of Advanced Medical Sciences, Tabriz University of Medical Sciences, Tabriz, Iran.
245    10
$a RGD delivery of truncated coagulase to tumor vasculature affords local thrombotic activity to induce infarction of tumors in mice / $c R. Jahanban-Esfahlan, K. Seidi, H. Monhemi, ADF. Adli, B. Minofar, P. Zare, D. Farajzadeh, S. Farajnia, R. Behzadi, MM. Abbasi, N. Zarghami, T. Javaheri,
520    9_
$a Induction of thrombosis in tumor vasculature represents an appealing strategy for combating cancer. Herein, we combined unique intrinsic coagulation properties of staphylocoagulase with new acquired functional potentials introduced by genetic engineering, to generate a novel bi-functional fusion protein consisting of truncated coagulase (tCoa) bearing an RGD motif on its C-terminus for cancer therapy. We demonstrated that free coagulase failed to elicit any significant thrombotic activity. Conversely, RGD delivery of coagulase retained coagulase activity and afforded favorable interaction of fusion proteins with prothrombin and αvβ3 endothelial cell receptors, as verified by in silico, in vitro, and in vivo experiments. Although free coagulase elicited robust coagulase activity in vitro, only targeted coagulase (tCoa-RGD) was capable of producing extensive thrombosis, and subsequent infarction and massive necrosis of CT26 mouse colon, 4T1 mouse mammary and SKOV3 human ovarian tumors in mice. Additionally, systemic injections of lower doses of tCoa-RGD produced striking tumor growth inhibition of CT26, 4T1 and SKOV3 solid tumors in animals. Altogether, the nontoxic nature, unique shortcut mechanism, minimal effective dose, wide therapeutic window, efficient induction of thrombosis, local effects and susceptibility of human blood to coagulase suggest tCoa-RGD fusion proteins as a novel and promising anticancer therapy for human trials.
650    _2
$a zvířata $7 D000818
650    _2
$a bakteriální proteiny $x genetika $x metabolismus $7 D001426
650    _2
$a nádorové buněčné linie $7 D045744
650    _2
$a kultivované buňky $7 D002478
650    _2
$a koagulasa $x genetika $x metabolismus $7 D003030
650    _2
$a lidé $7 D006801
650    _2
$a infarkt $x patologie $7 D007238
650    _2
$a myši inbrední C57BL $7 D008810
650    _2
$a myši nahé $7 D008819
650    _2
$a mutace $7 D009154
650    _2
$a nádory $x genetika $x metabolismus $x terapie $7 D009369
650    _2
$a patologická angiogeneze $x genetika $x metabolismus $x patologie $7 D009389
650    _2
$a oligopeptidy $x genetika $7 D009842
650    _2
$a rekombinantní fúzní proteiny $x genetika $x metabolismus $7 D011993
650    _2
$a trombóza $x genetika $x metabolismus $7 D013927
650    _2
$a tumor burden $x genetika $7 D047368
650    _2
$a xenogenní modely - testy protinádorové aktivity $x metody $7 D023041
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Seidi, Khaled $u Department of Medical Biotechnology, Faculty of Advanced Medical Sciences, Tabriz University of Medical Sciences, Tabriz, Iran.
700    1_
$a Monhemi, Hassan $u Structural Biology and Bioinformatics Research Group, Khayyam Bioeconomy Institute (KBI), Mashhad, Iran.
700    1_
$a Adli, Amir Daei Farshchi $u Department of Medical Biotechnology, Faculty of Advanced Medical Sciences, Tabriz University of Medical Sciences, Tabriz, Iran.
700    1_
$a Minofar, Babak $u Faculty of Science, University of South Bohemia, Branišovská 1760, 37005, České, Budějovice, Czech Republic. Center for Nanobiology and Structural Biology, Institute of Microbiology, Academy of Sciences of the Czech Republic, Zámek 136, 373 33, Nové Hrady, Czech Republic.
700    1_
$a Zare, Peyman $u Faculty of Veterinary Sciences, The University of Melbourne, Werribee, Victoria, Australia.
700    1_
$a Farajzadeh, Davoud $u Department of Cellular and Molecular Biology, Faculty of Biological Science, Azarbaijan Shahid Madani University, Tabriz, Iran.
700    1_
$a Farajnia, Safar $u Drug Applied Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.
700    1_
$a Behzadi, Ramezan $u North Research Center, Pasture Institute of Iran, Tehran, Amol, Iran.
700    1_
$a Abbasi, Mehran Mesgari $u Department of Cellular and Molecular Biology, Faculty of Biological Science, Azarbaijan Shahid Madani University, Tabriz, Iran.
700    1_
$a Zarghami, Nosratollah $u Department of Medical Biotechnology, Faculty of Advanced Medical Sciences, Tabriz University of Medical Sciences, Tabriz, Iran. Zarghami@tbzmed.ac.ir. Department of Clinical Biochemistry and Laboratory Medicine, Faculty of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran. Zarghami@tbzmed.ac.ir.
700    1_
$a Javaheri, Tahereh $u University of Veterinary Medicine, Ludwig Boltzmann Institute for Cancer Research, Institute for Animal Breeding and Genetics, Veterinärplatz 1, A-1210, Vienna, Austria. Tahereh.Javaheri@lbicr.lbg.ac.at.
773    0_
$w MED00182195 $t Scientific reports $x 2045-2322 $g Roč. 7, č. 1 (2017), s. 8126
856    41
$u https://pubmed.ncbi.nlm.nih.gov/28811469 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20190405 $b ABA008
991    __
$a 20190405092912 $b ABA008
999    __
$a ok $b bmc $g 1392403 $s 1051398
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2017 $b 7 $c 1 $d 8126 $e 20170815 $i 2045-2322 $m Scientific reports $n Sci Rep $x MED00182195
LZP    __
$a Pubmed-20190405

Find record

Citation metrics

Archiving options